Oral vs. Topical Minoxidil: What the Head-to-Head Trials Actually Show

Topical minoxidil has been available over the counter since 1988 and has been, for decades, one of two pharmacological pillars of androgenetic alopecia treatment, alongside finasteride. Our knowledge-base entry on minoxidil covers its mechanism in more depth — widening scalp blood vessels and prolonging the hair growth phase, a completely different mechanism than finasteride's DHT blockade.

In the past few years, alongside the classic solution and foam, a third option has emerged that's increasingly discussed in dermatology offices and on hair-loss forums: low-dose oral minoxidil, abbreviated in the literature as LDOM. Instead of a daily, twice-a-day application of a sticky liquid to the scalp — one pill, once a day. That convenience has driven a surge of interest that has partly outpaced how quickly science has been able to formally study and approve this use.

With the topical form, efficacy depends on several links in a chain, any of which can fail: how much of the drug actually penetrates the skin's stratum corneum, how precisely and consistently it's applied, and how much of the absorbed substance gets converted into active minoxidil sulfate by the sulfotransferase enzyme present locally in the hair follicle. With the oral form, the drug enters systemic circulation in a far more predictable way, independent of application technique, and conversion to the active form also happens in the liver, not just locally in the skin.

This distinction has practical relevance for two patient groups the literature describes: people with low sulfotransferase activity in the hair follicle, who respond poorly to the topical form no matter how carefully they apply it, and people with very low compliance with daily application (forgetting, inconvenience, irritation that prevents consistent use), for whom the oral form alone might improve the end result — not because the pill is 'stronger' in the target tissue, but simply because it's easier to actually take every day.

The dose here is worth noting: this trial used 5 mg/day orally in men — higher than the typical 1-2.5 mg used for women in other trials — which partly explains the very high hypertrichosis rate (49%) in this specific sample. A reminder that 'oral minoxidil' isn't one standardized dose, but a whole spectrum of doses with different risk profiles.

This is a separate, practical angle rarely covered in popular comparisons: the oral form isn't 'better overall,' but it can be better for specific groups of patients. The first group is people with documented, persistent intolerance to the topical form — chronic irritation, itching, or contact dermatitis that prevent regular use of the solution or foam regardless of how much they'd like to continue treatment.

The second group is people with a poor response to the topical form despite correct, consistent application for long enough (6-12 months) — for some of them, the cause is low sulfotransferase enzyme activity in the hair follicle, described in our minoxidil entry, which could theoretically be partly offset by a different metabolic route when the drug is given systemically. The third group is simply people with very low compliance with twice-daily application — for them, one morning pill can realistically be much easier to sustain for months, which has direct clinical significance, since no drug works if it isn't taken consistently.

It's also worth remembering that people with existing, even well-controlled cardiovascular disease were typically excluded from these trials, meaning the available safety data doesn't directly apply to this group — for them, a decision about possibly using the oral form requires a far more individualized cardiac evaluation.

Low-dose oral minoxidil is neither a miraculous, stronger substitute for the topical form nor a risky fad to be feared. It's a real, increasingly well-studied treatment option with a different, but not generally higher, risk profile — with a specific, well-identified group of patients for whom it may be a better practical choice than daily solution application. The key is that the decision to use the oral form should be made consciously, with a doctor, not as a self-directed online purchase based on enthusiastic forum opinions.